Adderall XR Cost in Hawaii 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Adderall XR Actually Cost in Hawaii Right Now?

The average cash-pay price for generic Adderall XR in Hawaii is approximately $30 per month in 2026, a steep drop from the $260 manufacturer list price for brand and generic products. The gap between list price and street-level cash price exists because independent discount programs, pharmacy buying groups, and GoodRx-style coupon aggregators compress the margin at the point of sale. Patients who walk in without a coupon and without insurance often pay closer to $80 to $120, so the method of purchase matters considerably.

Adderall XR is the extended-release capsule formulation of mixed amphetamine salts, a 75/25 ratio of dextroamphetamine and levoamphetamine salts [1]. The FDA approved the extended-release formulation for ADHD in children aged 6 and older, and later expanded the indication to adults [2]. Because it is a Schedule II controlled substance under the Controlled Substances Act, it cannot be dispensed without a valid written or electronic prescription from a licensed prescriber [3].

Price varies by capsule strength. A 30-count supply of 10 mg capsules typically costs less than 20 mg or 30 mg strengths because lower-dose capsules have higher dispensing volume and better generic competition. Costco and Walmart pharmacies in Honolulu have historically offered the lowest shelf prices among major chains, though independent pharmacies in Maui and the Big Island may match those prices when a GoodRx or SingleCare coupon is presented.

Patients traveling between islands should be aware that inter-island mail order from a mainland pharmacy is subject to the same Schedule II shipping restrictions that apply nationally. A Hawaii-licensed pharmacy must dispense the prescription within the state unless a DEA-registered mail-order pharmacy holds a Hawaii license [3].

The practical cost framework for Hawaii residents breaks into four tiers: (1) insured patients paying a copay, (2) uninsured or underinsured patients paying cash with a discount card, (3) Medicaid enrollees who must seek alternative coverage, and (4) patients who qualify for compounded mixed amphetamine salts through a 503A pharmacy program.

Does Hawaii Medicaid (Med-QUEST) Cover Adderall XR?

Hawaii Med-QUEST does not cover Adderall XR on its preferred drug list as of 2025 to 2026. This applies to both the brand product and generic mixed amphetamine salts extended-release capsules. The exclusion affects all four Med-QUEST managed care plans: AlohaCare, Kaiser Permanente, HMSA, and United Healthcare Community Plan [4].

Hawaii's Medicaid formulary does cover some immediate-release amphetamine products and methylphenidate-based alternatives such as Ritalin and Concerta generics. A prescriber who believes a patient requires the extended-release formulation specifically may submit a prior authorization (PA) request, but approval rates for XR formulations are low when an IR alternative exists on formulary [4].

The AHRQ's 2023 Comparative Effectiveness Review on ADHD pharmacotherapy confirmed that extended-release formulations generally produce equivalent symptom control to optimally titrated immediate-release regimens in head-to-head trials [5]. Medicaid programs cite that equivalence when justifying IR-first policies.

For Med-QUEST enrollees who cannot tolerate immediate-release products or who have documented adherence failures with IR formulations, the PA pathway is still worth pursuing. The treating clinician should document: (a) prior trial of a covered IR stimulant with inadequate response or intolerable adverse effects, (b) clinical rationale for the XR formulation specifically, and (c) functional impairment data such as school records or workplace documentation [4].

Children enrolled in the CHIP component of Med-QUEST face the same formulary restrictions. Parents should request a written denial from the managed care plan before appealing, because the denial letter triggers the formal grievance timeline under 42 CFR 438.402 [6].

What Private Insurance Plans Cover Adderall XR in Hawaii?

Most commercial plans available through the Hawaii Health Connector and employer group markets do cover generic mixed amphetamine salts XR, typically at Tier 2 or Tier 3. HMSA (the dominant Blue Cross Blue Shield affiliate in Hawaii) places generic amphetamine salts XR on Tier 2 for most group plans, producing a typical copay of $30 to $60 for a 30-day supply [7].

Kaiser Permanente Hawaii's formulary lists generic mixed amphetamine salts XR at Tier 2 as well, with a $20 to $40 copay for members using Kaiser pharmacies [7]. Out-of-network dispensing reverts to full list price minus any applicable discount.

United Healthcare plans sold in Hawaii vary by employer contract. Members should run a formulary check through the UHC online drug pricing tool before their first fill, because the same molecule can sit at Tier 2 on one group plan and Tier 4 on another depending on the employer's benefit design [8].

The Affordable Care Act requires that mental health and substance use disorder benefits be covered at parity with medical and surgical benefits under the Mental Health Parity and Addiction Equity Act (MHPAEA) [9]. ADHD pharmacotherapy for a diagnosed condition falls under this parity protection. If your insurer places stimulant medications at a higher cost-sharing tier than comparable non-psychiatric medications, a parity complaint to the Hawaii Insurance Division may be warranted [9].

Step therapy requirements are common. Most Hawaii commercial plans require a trial of at least one generic IR stimulant (typically amphetamine salts IR or methylphenidate IR) before approving the XR formulation at a preferred tier [8]. Document every prior trial carefully, including dates, doses, and the reason for discontinuation.

Is Compounded Mixed Amphetamine Salts Legal in Hawaii?

Yes. Licensed 503A compounding pharmacies operating in Hawaii may legally prepare compounded mixed amphetamine salts for individual patient prescriptions, provided the pharmacy holds a valid Hawaii Board of Pharmacy permit and the prescribing clinician has issued a patient-specific prescription [10]. This is the same legal framework that governs compounding of any Schedule II controlled substance at the state level.

Federal law under 21 U.S.C. 353a (the 503A statute) permits a licensed pharmacist to compound a drug product that contains a controlled substance when a licensed practitioner issues a valid prescription for an individually identified patient [10]. The pharmacy must source USP-grade active pharmaceutical ingredient (API) from a DEA-registered supplier. Bulk compounding of Schedule II substances for office use or resale without patient-specific prescriptions is prohibited under the same statute [10].

The DEA's 2023 rule on telemedicine and controlled substances created additional friction for new patients. Under the Ryan Haight Act and its 2023 amendments, a prescriber must conduct at least one in-person medical evaluation before issuing a Schedule II prescription via telemedicine for a new patient, unless the patient is being treated by a DEA-registered telemedicine platform operating under a special registration [11]. Hawaii has not enacted a state-level exception to this federal requirement.

Compounded mixed amphetamine salts are not FDA-approved, meaning they have not undergone the same bioavailability and bioequivalence testing as the branded Adderall XR product. Patients should discuss the clinical tradeoffs with their prescriber. The American Society of Health-System Pharmacists has noted that compounded stimulant preparations may differ in release kinetics from the commercial XR capsule [12].

Cost is the primary driver of interest in the compounded route. Some 503A pharmacy programs operating in Hawaii offer compounded mixed amphetamine salts at no out-of-pocket cost to the patient when dispensed as part of a telehealth-integrated care program. The economics work because the program absorbs pharmacy margin through the clinical service fee rather than the drug dispensing fee.

What Does the Clinical Evidence Say About Mixed Amphetamine Salts XR?

Mixed amphetamine salts extended-release has one of the best-studied efficacy profiles among ADHD medications. The landmark Multimodal Treatment Study of Children with ADHD (MTA, N=579) found that medication management with stimulants produced significantly greater reductions in ADHD symptom scores than behavioral treatment alone over 14 months (P<0.001) [13]. The MTA was not specific to the XR formulation, but it established the evidence base for amphetamine-class stimulants broadly.

The key Phase 3 trial supporting the Adderall XR FDA approval enrolled 584 children aged 6 to 12 and demonstrated statistically significant improvement on the ADHD Rating Scale IV at all doses (5 mg, 10 mg, 20 mg, and 30 mg) compared with placebo at week 3 [2]. A parallel adult study (N=255) showed a 5.4-point mean reduction in the Conners' Adult ADHD Rating Scale investigator-rated total score versus 1.5 points for placebo (P<0.001) [2].

A 2018 Cochrane systematic review of amphetamines for ADHD in adults (k=19 RCTs, N=2,521) concluded that amphetamine-class medications reduced ADHD symptom severity with a standardized mean difference of 0.37 (95% CI: 0.26 to 0.48) compared with placebo [14]. The review noted that the quality of evidence was moderate due to high dropout rates and variable outcome measures across trials, a finding that underscores the need for individualized dose optimization [14].

The FDA label carries a black box warning for potential for abuse and dependence, and for cardiovascular risk in patients with pre-existing structural cardiac abnormalities [2]. The American Heart Association recommends an electrocardiogram before initiating stimulant therapy in any child with a personal or family history of cardiac disease, syncope, or palpitations [15].

"Stimulant medications remain the most effective pharmacological treatment for ADHD across the lifespan," according to the 2019 American Academy of Pediatrics (AAP) Clinical Practice Guideline for ADHD, which recommends FDA-approved medications as first-line therapy for children aged 6 and older [16]. The same guideline notes that the choice between IR and XR formulations should reflect patient and family preference, school schedule, and coverage constraints [16].

How to Get Adderall XR via Telehealth in Hawaii

Telehealth prescribing of Adderall XR is permitted in Hawaii for established patients. The Hawaii Telehealth Act (HRS Chapter 453) allows licensed clinicians to prescribe within the scope of their practice via synchronous audio-video encounters [17]. Prescribing a Schedule II substance via telemedicine to a new patient still requires at least one prior in-person evaluation under the federal Ryan Haight Act, as noted above [11].

Patients who saw a clinician in person before the COVID-era telemedicine flexibilities ended and who have an established relationship with a Hawaii-licensed prescriber may continue receiving Adderall XR prescriptions via telehealth. The DEA's enforcement discretion guidance has been extended through at least late 2025, but patients and clinicians should verify the current status before relying on this pathway [11].

Hawaii-based telehealth ADHD platforms typically charge $150 to $250 for an initial evaluation and $75 to $125 per follow-up. These fees are separate from the drug cost. Some platforms include the compounded mixed amphetamine salts program described in the previous section, which can offset the drug cost entirely.

The Hawaii Medical Board requires that telehealth clinicians establish a valid patient-provider relationship before prescribing, including a review of the patient's prescription drug monitoring program (PDMP) record in Hawaii's Prescription Drug Monitoring Program (PDMP) [17]. Clinicians must check the PDMP before issuing any Schedule II prescription, regardless of whether the encounter is in person or via video [17].

What Discount Programs Are Available for Adderall XR in Hawaii?

Several discount mechanisms can reduce the cash-pay cost of generic Adderall XR below the $30 average already cited, and in some cases to under $10 for a 30-day supply.

GoodRx and SingleCare. These coupon aggregators negotiate rates with pharmacy benefit managers and pass savings to cash-paying patients. GoodRx prices for 30 capsules of generic mixed amphetamine salts XR 20 mg in Honolulu have ranged from $18 to $45 depending on the dispensing pharmacy. The coupon is presented at the pharmacy counter and is incompatible with insurance billing on the same transaction [18].

Manufacturer savings cards. Teva, the largest generic manufacturer of mixed amphetamine salts XR, has historically offered a savings card for commercially insured patients that reduces out-of-pocket cost to as low as $0 for a limited number of fills per year. The card is not valid for patients whose primary payer is a federal program (Medicare, Medicaid, TRICARE) [18]. Patients should check Teva's current savings card terms directly, because program parameters change annually.

340B program pharmacies. Federally qualified health centers (FQHCs) and other 340B-covered entities operating in Hawaii purchase medications at deeply discounted 340B prices and may pass those savings to uninsured patients. Waimanalo Health Center and Kokua Kalihi Valley Comprehensive Family Services are examples of FQHCs in Oahu that operate 340B pharmacies [19]. Availability of Adderall XR through these channels depends on formulary decisions made by each entity.

Patient Assistance Programs (PAPs). Brand Adderall XR (Takeda/Shire) has not been widely available in the U.S. market since the generic entry in 2009, so the Takeda PAP is of limited relevance. Generic manufacturers rarely operate formal PAPs. The NeedyMeds database lists state and federal programs that may cover stimulant costs for low-income Hawaii residents not covered by Medicaid [19].

Monitoring and Safety Requirements for Long-Term Use

Prescribers in Hawaii must comply with standard Schedule II monitoring requirements. These include: issuance of a new written or electronic prescription for each 30-day supply (no refills permitted on Schedule II prescriptions under 21 U.S.C. 829(a)) [3], PDMP review before each new prescription, and periodic reassessment of the ADHD diagnosis and treatment response.

The FDA label for mixed amphetamine salts XR recommends reassessing the long-term usefulness of the medication periodically, given that ADHD symptoms can change across developmental stages [2]. The AAP guideline recommends at minimum annual follow-up visits once the patient is stable, with more frequent contact during dose titration [16].

Cardiovascular monitoring should include blood pressure and heart rate at each visit. A 2012 study published in JAMA (N=443,198 person-years of follow-up) found no significant increase in the risk of serious cardiovascular events among current users of ADHD medications compared with non-users (adjusted hazard ratio 0.83 to 95% CI: 0.72 to 0.96) [20]. That reassurance does not eliminate the need for routine monitoring, particularly in patients with hypertension or known arrhythmia.

Growth monitoring is recommended for pediatric patients. Mixed amphetamine salts can suppress appetite and reduce height velocity in some children. The prescribing information recommends monitoring height and weight and considering treatment interruption if growth suppression is clinically significant [2]. A 2007 follow-up analysis of MTA participants found a mean height deficit of approximately 2 cm after 3 years of continuous stimulant treatment compared with unmedicated controls, though this difference attenuated over longer follow-up [13].

Sleep latency is a common complaint. The XR capsule releases approximately 50% of the dose immediately and 50% over 4 to 8 hours [2]. Patients who take the dose after 10 a.m. in Hawaii Standard Time (UTC-10) may experience difficulty initiating sleep. The standard clinical recommendation is to take the dose as early in the morning as feasible, ideally before 8 a.m. [16].